Opdivo tops Yervoy in melanoma win analyst says could pad Bristol-Myers' I-O sales by $1B
admin 6th July 2017 Uncategorised 0Bristol-Myers Squibb’s battered Opdivo registered a positive surprise Wednesday, topping fellow BMS checkpoint med Yervoy in an adjuvant melanoma trial. And while the news may not have wowed investors, some analysts say it could give the company’s top line a serious lift.
More: Opdivo tops Yervoy in melanoma win analyst says could pad Bristol-Myers' I-O sales by B
Source: fierce